Merck KGaA says Q2 operating profit rises 15%

Tourism

German drugs and chemicals company Merck KGaA reported a 15% rise in Q2 operating profit on Wednesday thanks to rising sales of liquid crystals and multiple-sclerosis and cancer drugs.

Operating profit rose to €320.5 million ($510 million) from €277.5 million  a year earlier, slightly missing the average estimate of €326 million in a Reuters poll of 15 analysts.

“Currency effects continued to have a considerable negative impact on total revenues,” the company said in a statement.

Merck KGaA said total revenues grew organically by 12% but this was reduced by 6.1 percentage points due to translation of local currencies into the strong euro.

Sales of its cancer medicine Erbitux rose 24% in the second quarter, while sales of its multiple-sclerosis drug Rebif increased 2.8%.

Merck KGaA is also the world's largest supplier of the liquid crystal compounds used in televisions, mobile phones and computer laptops.

Liquid crystals sales rose 7% to €238 million, despite negative currency effects. The operating profit margin for this business dipped to 45% in the quarter.

For 2008, Merck reiterated it expected group revenue to grow 5%-9% and its operating margin - excluding amortization and integration costs - to be 23%-27%.

Merck KGaA shares have fallen about 10% this year, roughly in line with the pan-European DJ Stoxx chemicals index and the drugs sector index , partly on worries over the impact of a slowdown in the US economy.

According to Reuters data, Merck shares trade at 16 times estimated 2009 profit, a premium to the chemicals and drugs sectors' 12 times thanks partly to upbeat outlook for Erbitux. (Reuters)

ADVERTISEMENT

European e-commerce soars during pandemic - study Analysis

European e-commerce soars during pandemic - study

Lawmakers approve 2022 budget Parliament

Lawmakers approve 2022 budget

Duncan Graham reelected as BCCH president Appointments

Duncan Graham reelected as BCCH president

Chain Bridge to be closed for traffic for 18 months City

Chain Bridge to be closed for traffic for 18 months

SUPPORT THE BUDAPEST BUSINESS JOURNAL

Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.